FibroBiologics, Inc.
FBLG
$0.96
$0.033.23%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -54.13% | 43.86% | -24.04% | 6.20% | -60.25% |
| Total Depreciation and Amortization | 1.28% | 1.30% | 12.14% | 27.95% | 5.23% |
| Total Amortization of Deferred Charges | -- | -- | -100.00% | -- | -- |
| Total Other Non-Cash Items | -45.90% | -22.02% | 371.12% | -70.32% | 613.82% |
| Change in Net Operating Assets | 81.96% | -2,403.45% | 112.11% | 69.20% | -457.35% |
| Cash from Operations | -37.97% | 20.37% | 0.30% | 24.47% | -71.66% |
| Capital Expenditure | -- | 100.00% | 97.18% | -395.35% | 56.57% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 100.00% | 97.18% | -395.35% | 56.57% |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | 97.62% | -- | -- | -- | -- |
| Issuance of Common Stock | -89.29% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -70.16% | -- | -100.00% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -12,737.04% | 100.68% | -2,334.83% | 103.35% | -186.36% |